Decoding Risks and Rewards in Ischemic Stroke Surgery

Sponsor
China Medical University Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT06098066
Collaborator
(none)
204,411
1
33
6190.8

Study Details

Study Description

Brief Summary

In the high-stakes battle against ischemic cerebrovascular disease, where every second counts and the margin for error is slim, how do the investigators tip the scales in favor of patient survival and improved outcomes? This groundbreaking study, the first nationwide, population-based analysis with long-term follow-up in an Asian context, dives deep into this critical question. Leveraging an expansive dataset from Taiwan's National Health Insurance Research Database, the investigators scrutinize the efficacy and risks of aggressive surgical interventions-specifically, EC-IC bypass, CEA, and CAS-in a cohort of over 84,000 patients.

This paper serves as a milestone, bridging the gap between medical idealism and clinical reality. It calls for a surgical renaissance, emphasizing the need for refining techniques and enhancing patient selection protocols. If participants're looking for a comprehensive, nuanced, and, above all, actionable insight into the surgical treatment of ischemic cerebrovascular disease, this is the study that could redefine the paradigm.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    204411 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Decoding the Surgical Enigma: A Groundbreaking Nationwide Study Unveils the Risks and Rewards of EC-IC Bypass, CEA, and CAS in Ischemic Cerebrovascular Disease
    Actual Study Start Date :
    May 1, 2020
    Actual Primary Completion Date :
    May 30, 2020
    Actual Study Completion Date :
    Jan 31, 2023

    Arms and Interventions

    Arm Intervention/Treatment
    control

    ECIC bypass

    CEA

    CAS

    Outcome Measures

    Primary Outcome Measures

    1. rehospitalization [Follow-up assessments were planned at 3 months, 6 months, 1 year, 2 years, and 3 years post-index date]

      rehospitalization due to ischemic or hemorrhagic stroke

    Secondary Outcome Measures

    1. Cardiac events [Follow-up assessments were planned at 3 months, 6 months, 1 year, 2 years, and 3 years post-index date]

      congestive heart failure and acute myocardial infarction were also monitored throughout the study period.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • All participants underwent either a computed tomography (CT) scan or magnetic resonance imaging (MRI) within two days before or after hospital admission.

    The date of the first ischemic stroke hospitalization served as the index event.

    Among these patients, those who underwent surgical interventions post-hospitalization were categorized into three distinct groups: CEA (ICD-9-CM code 3812), CAS (ICD-9-CM code 3990), and EC-IC (ICD-9-CM code 3928), with the operation date being the index date.

    Those who did not receive any surgical interventions were considered the non-intervention control group and had their first hospitalization date as the index date.

    Exclusion Criteria:
    • patients with a history of: any stroke subtype (ICD-9-CM codes 430-434), Moyamoya disease (ICD-9-CM code 437.5), cancer (ICD-9-CM codes 140-239), trauma (various ICD-9-CM codes), transient ischemic attack (ICD-9-CM code 435), unruptured cerebral aneurysm (ICD-9-CM code 437.3), or subarachnoid hemorrhage (ICD-9-CM code 430).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 China Medical University Hospital Taichung Taiwan

    Sponsors and Collaborators

    • China Medical University Hospital

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    XianXiu Chen, Clinical Researcher, China Medical University Hospital
    ClinicalTrials.gov Identifier:
    NCT06098066
    Other Study ID Numbers:
    • NS01
    First Posted:
    Oct 24, 2023
    Last Update Posted:
    Oct 24, 2023
    Last Verified:
    Oct 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by XianXiu Chen, Clinical Researcher, China Medical University Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 24, 2023